Form 4: Provectus Biopharmaceuticals CTO, Eric Wachter, Acquires Stock Options

Eric Wachter, CTO of Provectus Biopharmaceuticals, acquired 2,138,548 stock options on December 2, 2024, which vest in three equal annual installments.

Summary

• Eric Wachter, the Chief Technology Officer of Provectus Biopharmaceuticals, was granted 2,138,548 stock options on December 2, 2024.
• These options have an exercise price of $0.2862 per share.
• The options vest in three equal annual installments, starting on December 2, 2024.
• The options expire on December 2, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The grant of stock options to the CTO may align his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CTO.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize executives.
• The vesting schedule of three equal annual installments is also a common practice.
• The exercise price of $0.2862 is specific to Provectus Biopharmaceuticals and its current stock valuation.

Stakeholder Impact

• The stock option grant may be viewed positively by shareholders as it incentivizes the CTO to work towards increasing the company's value.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock options, Provectus Biopharmaceuticals, Eric Wachter, CTO, insider trading, equity compensation